Mar 3, 2025 · Trastuzumab deruxtecan is FDA-approved for the treatment of HER2-positive metastatic breast cancers that have progressed on at least one past HER2-targeted therapy …

Learn about Herceptin® (trastuzumab), a targeted therapy approved for HER2+ metastatic breast cancer treatment. See full safety & Boxed Warnings for more information.

Trastuzumab (brand name: Herceptin) is a targeted therapy known as a monoclonal antibody, a modified version of an immune system protein, that can attach to proteins on HER2-positive …

4 days ago · Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall response rate compared to chemotherapy. …

Targeted therapies—a form of precision medicine—have represented some of the most important breakthroughs in breast cancer research. Today, oncologists have numerous targeted …

Apr 17, 2025 · Learn how targeted therapies, including monoclonal antibodies (such as Herceptin or Trastuzumab), can be used to treat breast cancer.

Jun 17, 2025 · The current treatment landscape for HER2-positive metastatic breast cancer has evolved significantly, with recent updates further refining patient care strategies. Historically, …

On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first …

Aug 10, 2021 · Targeted Drug Therapy for Breast Cancer Targeted drug therapy uses medicines that are directed at (target) proteins on breast cancer cells that help them grow, spread, and …

Trastuzumab (Herceptin) is a targeted therapy for treating breast cancer. Find out when it's used, how it works and possible side effects.